POF (paclitaxel/oxaliplatin/5-fluorouracil/leucovorin) vs. SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial

POF (paclitaxel/oxaliplatin/5-fluorouracil/leucovorin) vs. SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial

BackgroundPostoperative chemotherapy is a standard treatment for stage II and III gastric cancer in Asia. With regard to single-agent or doublet, the need for improvement has consistently been pointed out because of the relatively poor outcome for patients with stage III gastric cancer. Triplet has...

Full description

Bibliographic Details
Main Authors: Liyu Su, Shen Zhao, Yi Yin, Feng Huang, Jinfeng Zhu, Luchuan Chen, FNF Independent Investigations Group, Rongbo Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Medicine
Subjects:
gastric cancer
adjuvant chemotherapy
POF
disease-free survival
survival
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.861777/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.861777/full

Similar Items